Immunotherapy Navigated by Serum Presepsin for Infections of the Respiratory Tract: the INSPIRE Double-blind, Randomized, Phase IIa Exploratory Trial.
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 60
- 试验地点
- 5
- 主要终点
- Change of Sequential Organ Failure Assessment score by day 7 or death by day 90.
研究概览
简要总结
The current study is an exploratory, phase IIa randomized clinical trial (RCT) aiming to evaluate if early presepsin increase coupled with early initiation of anakinra as an adjunct therapy to the standard-of-care treatment may improve outcomes of community-acquired pneumonia or hospital-acquired pneumonia.
详细描述
Sepsis is a potentially lethal syndrome, which is characterized by the dysregulated response of the host to an infection. Due to its severity, sepsis should always be considered in patients with confirmed or suspected infection as it can rapidly progress to organ failure with poor prognosis. Conversely, patients with new-onset organ failure should be suspected for occult infection. Current epidemiology is suggesting an increase in the incidence of new cases. Sepsis has considerable economic burden on the community as septic patients merit higher-level of healthcare and prolonged hospital stay. Subsequently, prompt recognition and treatment are of essence in order to mitigate the overall toll.
In the past years, numerous efforts have been made to identify a biomarker that portends the presence of sepsis, but none has managed to consistently predict which patients will eventually develop this syndrome. This is largely attributed to still-unknown host and pathogen mechanisms by which the sepsis cascade is initiated. Therefore, further understanding of the pathophysiology is of paramount importance.
The pathogenesis of sepsis is multifaceted and includes immune, cardiovascular, coagulation and metabolic perturbations. Immune dysregulation is a well-established component that leads to tissue injury. Activation of the innate immunity is a crucial step in the sequence of the upcoming events. As such, if we manage to early recognize the activation of one specific immune pathway during the initial stages of sepsis in the human host and promptly commence immunotherapy directed against this specific pathway, we may prevent the cascade of events leading the patient to life-threatening organ dysfunction. This paradigm of timely intervention on the immune system upon early recognition of a specific pathway activation is the SAVE-MORE trial in COVID-19. Preemptive initiation of anakinra treatment guided by the early increase of the biomarker suPAR (soluble urokinase plasminogen activator receptor) well before clinical signs of deterioration develop led to a 64% overall improvement and a 55% relative decrease in mortality. This early personalized treatment was registered in December 2021 by the European Medicines Agency.
One similar cascade of events is happening in sepsis. Bacterial lipopolysaccharide (LPS) of the cell membrane of Gram-negative bacteria and danger-associated molecular patterns (DAMPs) like high-mobility group box-1 (HMGB1) and mitochondrial DNA (mtDNA) are recognized by toll-like receptors (TLRs). Cluster of Differentiation 14 (CD14) is the naturally occurring receptor of LPS on the surface of monocytes/macrophages and the regulator of TLR-4 signal transduction. In 2004, a novel form of CD14, named soluble CD14 subtype (sCD14-ST) or presepsin was found significantly increased in patients with sepsis. Numerous studies have validated its use as an early indicator of sepsis, but a definite cut-off value has not been established due to the heterogeneity in the study design, selection of patients and clinical context. Once LPS binds and activates TLR-4, production of interleukin (IL)-1 ensues. As a consequence, early detection of increased presepsin coupled with anakinra, one short half-life inhibitor of the activity of IL-1α and IL-1β, may be a promising personalized treatment strategy for sepsis.
In recent years, studies conducted by the Hellenic Sepsis Study Group have shown that presepsin levels over 350 pg/ml have satisfactory diagnostic and prognostic value for sepsis. In particular, results from the INTELLIGENCE-1 study showed that in patients with at least one of the qSOFA criteria, presepsin more than 350 pg/ml has a sensitivity for diagnosing sepsis and 28-day mortality of 80.2% and 91.5%, respectively. Similar results were reproduced by 2 more independent studies; INTELLIGENCE-2, which also included patients with qSOFA ≥ 1 and SAVE trial, which investigated patients with COVID-19.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
盲法说明
This study is designed to maintain blinding from participants, site investigators and their teams until completion of the study. At each center, there will be an unblinded pharmacist (and one substitute) who will be in charge of randomizing and preparing the study drug for each participant according to the randomized intervention assignment. These pharmacists will not be involved in data acquisition, collection, adjudication of outcomes or adverse events, or any other study procedures. They will not disclose the treatment assignment to the study team members unless it is via a formal process of early unblinding as described below.
Αn independent biostatistician will generate the assignment to blinding treatment.
Under normal circumstances, all the treatment assignments of participants will remain blinded until the completion of the trial (completion of enrollment and follow-up or early termination of the trial).
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age equal to or above 18 years
- •Male or female gender
- •In case of women of reproductive age, willingness to use dual contraceptive method during the study period
- •Written informed consent provided by the patient. For subjects without decision-making capacity, informed consent must be obtained from a legally designated representative following the national legislation in the Member State where the trial is planned
- •Community-acquired pneumonia or hospital-acquired pneumonia
- •qSOFA score equal to 1
- •Serum presepsin > 350 pg/ml
排除标准
- •Age below 18 years
- •Denial of written informed consent
- •Any stage IV malignancy
- •Any do not resuscitate decision
- •Patients with PaO2/FiO2 less than 150 necessitating non-invasive ventilation or mechanical ventilation
- •Hospitalization in Intensive Care Unit
- •Known hypersensitivity to anakinra
- •Oral or IV intake of corticosteroids at a daily dose equal to or greater than 0.4 mg/kg prednisone for a period greater than the last 15 days
- •qSOFA score 0, 2 or 3
- •Any anti-cytokine biological treatment for the last one month
- •Pregnancy or lactation. Women of child-bearing potential will be screened by a urine pregnancy test before inclusion in the study
- •Participation in any other interventional trial
研究组 & 干预措施
Placebo
Treatment Arm 1: patients receiving placebo (N/S 0.9% w/v) subcutaneously once daily for 10 days plus Standard of Care
干预措施: Placebo (Drug)
Anakinra
Treatment Arm 2: patients receiving anakinra subcutaneously 100 mg once daily for 10 days plus Standard of Care
干预措施: Anakinra Prefilled Syringe (Drug)
结局指标
主要结局
Change of Sequential Organ Failure Assessment score by day 7 or death by day 90.
时间窗: 90 days
Patients who meet any of the following are considered to meet this endpoint: i) increase of Sequential Organ Failure Assessment score by 2 or more points from day 1 (before start of the study drug) until day 7; ii) death by day 90. Higher scores of the Sequential Organ Failure Assessment score indicate worsening of organ function, where the lowest score is 0 and highest is 24 (death).
次要结局
- 28-day organ dysfunction(28 days)
- Concentration of presepsin(10 days)
- Time to hospital discharge(28 days)
- Change in concentration of cytokines(7 days)
- Concentration of endothelial dysfunction markers(7 days)
- Change of Sequential Organ Failure Assessment score of screening failure subjects(10 days)
- 28-day mortality of screening failure cases compared with placebo(28 days)
- 28-day mortality(28 days)
- 90-day mortality(90 days)
- Change of Sequential Organ Failure Assessment score(28 days)
- Time to inflammation discontinuation(7 days)